About Nura Lyfe Sciences


Who we are

Developing safe, effective alternative medicine with psychedelic and cannabinoid derived molecules

Safety & Efficacy

Phased studies to ensure psychedelic and cannabinoid molecules are safe and effective for use in central nervous system disorders.


Working with regulatory academic & government bodies providing knowledge and education of emerging botanical medicine. Ensuring all medicine development procedures meet regulatory body protocols (FDA, EMA, MRA-FDA & SAHPRA)

Drug Development

Pioneering botanical medicine development, ultimately in-market use of derived psychedelic and cannabinoid treatment of depression, anxiety and pain

Intellectual Property

Developing proprietary formulations, combinations and trial data to support in- market use for patients across the world

Leadership Team

Aaron Katerenchuk

Chief Executive Officer
Aaron is a professional engineer holding a BSc Engineering from the University of Alberta, Canada. Aaron has 11 years experience in oil & gas specializing in project management with recent focus in acquisitions and dispositions (closing and integrating $100+ million-dollars in transactions). More recently Aaron held a position with Vibe Bioscience as Vice President of Business Development, facilitated in the process of taking Vibe public in Spring 2019 listing on the Canadian Securities Exchange. Aaron’s core focus at Vibe was product development (THC and CBD concentrates), retail, cultivation and evaluating acquisition opportunities. He has spent four years directly involved in the cannabis space with investment in cultivation, US retail and e-commerce companies both private and public.

Theodoros Makrygiannis

Head of Product Development

Theodoros is a graduate from the University of Patras specializing in Biochemistry & Biotechnology. Theodoros was born in Vonitsa, Greece and currently holds position as Quality Assurance Director. He has over 15 years experience in management positions in the pharmaceutical sector. Theodoros has held positions in Quality Assurance and as a Qualified person for companies such as Uni Pharma S.A. and Layipharm S.A.

Donaghue Woodman

Chief Science Officer
Donaghue’s role relates to regulatory aspects of the business, as well as new product and portfolio development and new business and strategic research development. Donaghue holds an MBA with a background in biochemistry and pharmacology (focusing on active molecules in natural medicines) with the South African Herbal Medicine and Science Institute. Donaghue has 9 years of sales and marketing experience within the pharmaceutical industry, in both the public and private sector, across a broad range of therapeutic areas including Woman’s health, CNS, Respiratory, Gastroenterology, Anaesthesiology, dermatology, Cystic Fibrosis, Pancreatic Cancer and Pain. Her passion is philanthropy, people and business, and she is a keynote motivational speaker for the Global Business Roundtable.

Greg Bealer

Chief Financial Officer
Greg obtained his Bachelor of Commerce degree majoring in Business Law and Economics from the University of Alberta, Canada. Greg recently retired after 11 years as an Investment Advisor and Portfolio Manager. He turned his core focus on the pharmaceutical and cannabis industry in 2013. Greg has been actively involved in financing of Canadian and international cannabis startups and brings both experience and knowledge of the capital markets.

Board of Directors​

Stephen Polakoff

Senior Legal Advisor
Stephen has over 20 years of experience as general counsel, legal advisor, director and project manager at corporations, funds, law firms including Deutsche Bank (UFG), Integra Group, Clifford Chance, Damac Properties and several funds. He has gathered international experience having worked in New York, Moscow, Dubai and Geneva. His experience has been very diverse across sectors and territories including joint ventures and M&A, capital markets, debt and equity financing, infrastructure and funds. He has served on the boards of AIM, TSX and AIM-listed entities as well as several funds. Stephen graduated from Georgetown University Law School and is a member of the New York Bar. He speaks English and Russian and currently resides in Barcelona.

Dr. Mookho Malahleha-Malahleha

Medical Advisor
Dr Mookho is a qualified clinician with extensive experience in HIV, TB and Covid vaccine clinical trial research. She holds a Bachelors Degree in Medicine and Surgery – UKZN, Diploma in HIV Management – Colleges of Medicine South Africa, Good Clinical Practice certified, Research Ethics certified, Masters in Public Health – University of Limpopo, Medunsa.

Dr. Naveen Basappa

Medical Oncologist
Naveen obtained his MD from the University of Alberta and currently Associate Clinical Professor in the Department of Oncology at the University. He is also the principal or co-investigator of multiple national and international clinical trials and actively conducts clinical research

Robert Matthews

Chartered Accountant
Mr. Matthews is a CA, graduating from the University of Alberta with 40 years experience in business. Mr. Matthews previously was the CFO of Brett Resources and Viceroy Exploration. Mr. Matthews was also VP/Controller for MacMillan Bloedel for 15 years and formally Price Waterhouse Coopers.

Anastase Maragos

Senior Legal Advisor
Graduated from the University of British Columbia holding a degree in Law. Over 15 years experience with public companies in technology and energy. Held director role with public company Edgewater Wireless

Advisory Board & Research Partners

Mahasarakham University Udonthani Cancer Hospital

Dr. Isara Chiawiriyabunya Director of UdonThani Cancer Hosptial
Based out of Thailand, conducting research on local Thai herb botanicals with cannabinoid combinations for the treatment of cancer pain and treatment of opioid dependency

Stellenbosch University

Head of Psychiatry - Professor Soraya Seedat
Research and development partnership for the psychedelic and cannabinoid trials in South Africa. Prof Seedat holds Chair position for South African Research in PTSD with the Department of Science and Technology and National Research Foundation. She has co-authored over 170 peer reviewed papers and extensive research with anxiety disorders

TASK Clinical Research

CRO South Africa
Clinical research partnership providing protocol development, trial facilities, regulatory submissions and trial consultation. TASK is currently running a COVID 19 vaccine trial in South Africa helping progress vaccination throughout the continent. TASK has completed multiple research projects, many of global significance and contributed to progressing the scientific field of TB medicine and vaccine development
Scroll to Top

Coming Soon